- Timo grimmer is in the team - All endpoints of the clinical trial were reached I firmly believe that the drug works and that the CEO has done a good job no matter how much he is criticized.

$BIVI what a difference it can make to have a strong ceo: Cuong Do (president & ceo): Former President of Samsung Global Strategy Group and former Chief Strategy Officer for Merck - expect the coming 14 days to be really exciting !!

No scam here, just great science, great fiscal Management and a CEO fixated on precision rather than stock price.

Hahah the CEO is hilarious!!

The interactions with their lead investigator, Dr. MacFarlane, and the BIg pharma executive are incredible since most investors would never be able to access the thoughts of people in those positions regarding their biotech investment(s) Amazing stuff.

$cosm “Greg Siokas, Chief Executive Officer of Cosmos Health stated, "I am excited to see Cosmos emerge in to in a stronger financial position.

Perfect video for my 2 favorite CEOs, Christopher Missling and Peter Greenleaf of AUPH.

$AVXL always good to see when the CEO is a PHD.

In fact, I would argue that this has been the defining moment he has been dreaming about since he became CEO.

That would keep Anavex relevant all week, and most importantly providing the opportunity for Chris and the executive team to connect with major pharma companies (suitors) the entire week while here in San Fran.

$BIVI what a difference it can make to have a strong ceo: Cuong Do (president & ceo): Former President of Samsung Global Strategy Group and former Chief Strategy Officer for Merck - expect the coming 14 days to be really exciting !!

Remi did an excellent job in securing his job as CEO in this regard.

$DRRX $SAVA Having a Vet as CEO is actually an advantage IMO.

$SAVA “We are thrilled with the progress made to date in the clinical development of simufilam, our oral drug candidate for people with Alzheimer’s disease,” said Remi Barbier, President & CEO.

“We are thrilled with the progress made to date in the clinical development of simufilam, our oral drug candidate for people with Alzheimer’s disease,” said Remi Barbier, President & CEO.

“We are thrilled with the progress made to date in the clinical development of simufilam, our oral drug candidate for people with Alzheimer’s disease,” said Remi Barbier, President & CEO.

$SAVA “We are thrilled with the progress made to date in the clinical development of simufilam, our oral drug candidate for people with Alzheimer’s disease,” said Remi Barbier, President & CEO.

He’s going to be flying with a golden parachute like one of dem big shot CEO’s

$SAVA In fact, Remi Barbier, President and CEO, said there were three benefits: “Simufilam improved cognition, biomarkers and behavior, a triple-win for study participants.

$SAVA BIIB executive are smart.

It was all really positive and nice to hear it from the CEO vs just Springer.